Lincoln Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Lincoln Pharmaceuticals Ltd is ₹ 618 as of 17 Feb 16:01 . The P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 7.2 on March 2021 to 13.4 on March 2025 . This represents a CAGR of 13.23% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 449.4 crore on March 2021 to ₹ 1104 crore on March 2025 . This represents a CAGR of 19.71% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 181.47 crore as compare to the Sep '25 revenue of ₹ 170.6 crore. This represent the growth of 6.37% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lincoln Pharmaceuticals Ltd for the Dec '25 is ₹ 38.74 crore as compare to the Sep '25 ebitda of ₹ 32.66 crore. This represent the growth of 18.62% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 23.67 crore to ₹ 28.6 crore over 7 quarters. This represents a CAGR of 11.42% The net profit of Supriya Lifescience Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 4.83 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of -1.94% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
All the assets and business of the erstwhile partnership were transferred to the Company.
The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Lincoln Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Lincoln Pharmaceuticals Ltd is 1,292 Cr while Market cap of Supriya Lifescience Ltd is 5,589 Cr

What are the key factors driving the stock performance of Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of May 4, 2026, the Lincoln Pharmaceuticals Ltd stock price is INR ₹645.4. On the other hand, Supriya Lifescience Ltd stock price is INR ₹694.5.

How do dividend payouts of Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Lincoln Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.